Senisca Secures Funding for Age-Related Disease Treatment

Senisca, a biotech company from Exeter, UK, has raised £3.7M in funding to develop RNA-based senotherapeutics for age-related diseases. The total funding now stands at £7.1M, with support from various investors including Emerging Longevity Ventures, QantX, R42 Group, Trend Investment Group, Apex Ventures, and Lifespan Vision Ventures. Led by CEO Dr. Sarah Cole, Senisca focuses on RNA splicing regulation to reprogram senescent cells and modify age-related diseases. The company's innovative approach targets cellular pathways for disease modification and skin health indications. With a strong focus on research and development, Senisca aims to generate IND data for future advancements in senotherapeutics.